Poly Medicure Ltd Q2 FY27 Results Due By 14 November

Poly Medicure Ltd's Q2 FY27 results date was unconfirmed as of 15 September 2026, while listing rules set 14 November 2026 as the outer deadline for the September-quarter filing. The company reported ₹525 crore revenue in Q1 FY27, making its Q2 comparison with the ₹444 crore year-ago base important for investors.

When will Poly Medicure report Q2 FY27 results?

Poly Medicure had not confirmed a board meeting date for its Q2 FY27 results as of 15 September 2026. The company had also not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter at that point, according to the available investor-relations material.

The Q2 FY27 reporting period runs from 1 July 2026 to 30 September 2026. Under Indian listing requirements, quarterly results for this period must be published within 45 days of the quarter end, placing the outer reporting deadline on 14 November 2026. Any date circulated before a formal exchange filing should therefore be treated as unverified.

The supplied market information also identifies 5 November 2026 as an expected earnings date. However, the company-specific material states that the Q2 date was not confirmed. The formal board-meeting intimation and results filing remain the relevant disclosures for confirming the timing.

What financial base will Poly Medicure's Q2 FY27 performance face?

Poly Medicure's September 2026-quarter results will be assessed against revenue of ₹444 crore and net profit of ₹92 crore reported in Q2 FY26. These reported figures for the September 2025 quarter provide the direct year-on-year comparison for the upcoming filing.

The latest reported quarter, Q1 FY27, showed revenue of ₹525 crore, up 30.27% from ₹403 crore in Q1 FY26. Net profit for Q1 FY27 was ₹85 crore, down 8.60% from ₹93 crore in the corresponding previous-year quarter. The difference between revenue growth and net-profit movement will make margins and expense trends relevant in the Q2 disclosure.

No verified consensus forecast for Poly Medicure's Q2 FY27 revenue or profit is included in the available material. As a result, the reported September-quarter numbers, rather than an assumed market estimate, will be the appropriate basis for evaluating quarterly and annual changes.

What is supporting Poly Medicure's longer-term growth plan?

Poly Medicure has identified global expansion, innovation and acquisitions as drivers of growth and margin improvement in its investor presentation. The company manufactures medical devices and disposables, including IV cannulas, catheters and other single-use healthcare products, and has a sizeable export base.

For the year ended 31 March 2026, the chairman's message reported revenue from operations of ₹1,875.26 crore, up 12.3%, and total income of ₹1,995.34 crore, up 13.4%. Consolidated EBITDA was ₹457.70 crore, while the company cited a standalone EBITDA margin of 26.8%.

Consolidated profit after tax for the year was ₹321 crore. Poly Medicure also reported liquidity of more than ₹800 crore, which management described as providing financial flexibility for future strategic growth opportunities. The available material refers to a ₹2,400 crore FY27 revenue target, placing quarterly revenue disclosures in the context of that stated goal.

Why do Poly Medicure's Q2 numbers matter to investors?

Poly Medicure's Q2 FY27 filing matters because it will show whether the company has sustained the revenue momentum reported in Q1 while addressing the lower year-on-year net profit recorded in that quarter. Investors can compare revenue and profit with both the immediate Q1 FY27 figures and the Q2 FY26 base.

The results will also provide updated information on operating profitability, exports, product demand and progress on the company's global expansion and innovation initiatives, to the extent disclosed by management. Since Poly Medicure operates in medical devices and disposables, reported performance can also offer a view of conditions in its core healthcare-product operations.

The annual figures indicate that the company entered FY27 with a profitable operating base and substantial liquidity. But the supplied information does not provide a numerical Q2 forecast or confirm how much of the FY27 revenue target has been achieved. The exchange filing will therefore be more informative than pre-result projections.

How should investors read the forthcoming results disclosure?

Investors should first compare the Q2 FY27 revenue figure with ₹444 crore in Q2 FY26 and ₹525 crore in Q1 FY27. They should then assess net profit against the ₹92 crore earned in the year-ago quarter and the ₹85 crore reported in Q1 FY27, while considering any management explanation for margin movement.

The filing's notes to accounts, operating-profit data and management commentary will be relevant alongside headline revenue and profit. Investors may also look for updates on acquisitions, export activity, product innovation and capital deployment, given the company's stated growth strategy and liquidity position.

Conclusion

Poly Medicure's immediate disclosure point is clear: its Q2 FY27 results date was not formally confirmed as of 15 September 2026, but the September-quarter filing was required by 14 November 2026. The forthcoming results will be measured against a ₹444 crore revenue and ₹92 crore profit base from Q2 FY26, following Q1 FY27 revenue of ₹525 crore.

The next item to watch is the company's formal exchange intimation and subsequent results filing. Investors will be looking for reported progress toward the stated ₹2,400 crore FY27 revenue target, as well as details on profitability, global expansion, innovation and acquisitions.